The short answer: choosing a contract development and manufacturing organization comes down to five things, in this order: their technical capability for your specific modality, their inspection history at the specific site, whether your capacity is truly reserved, whether the site can scale you to commercial, and their quality culture. Price should be near the bottom of that list. Most companies get this backward and select on price and reputation, which are the two least predictive inputs.
Here is how to run the selection properly, because more programs die in manufacturing than most people realize.
Why CDMO selection is so high stakes
A large share of Complete Response Letters from the FDA have nothing to do with the drug. They cite the facility, the process, the validation, or the third party who made the product. The molecule worked. The company still lost a year, and sometimes lost the company.
This is also the decision biotech companies are least equipped to make. A clinical stage company has scientists and clinicians, but rarely someone who has run a manufacturing site or negotiated a capacity reservation. So the choice gets made on a proposal and a familiar name, which is how the wrong CDMO gets selected.
The five types of CDMO
- The large integrated network. Global scale and regulatory track record, but you are a small customer competing internally for attention.
- The mid tier specialist. The best balance for most clinical stage companies. Real depth, and you matter as a customer.
- The modality boutique. Deep specialists in a hard modality such as cell or gene therapy. They can do it, but watch financial durability and the scale up cliff.
- The regional or cost advantaged site. Increasingly capable, but adds regulatory scrutiny and supply chain distance.
- The captive or divested site. Serious infrastructure at a good price, but a culture built to serve one internal customer.
The criteria that actually predict success
Score every candidate on the same sheet, weighted like this:
- Technical capability for your modality (25%). Can they make your product, at your spec, reproducibly. Ask for a comparable process, not a comparable client logo.
- Regulatory and inspection history (20%). Every FDA Form 483 and inspection outcome for the specific site, not the corporate parent.
- Capacity, and whether it is really yours (15%). Whether your slot is contractually protected when a larger customer arrives.
- Scale up path (15%). Whether this site can take you to commercial, or you will be transferring in three years.
- Quality systems and transparency (10%). How fast they tell you when something goes wrong.
- Project management (10%). Who your contact is and how many other programs they carry.
- Price (5%). The bid is not the price. The final invoice is.
The questions to ask before you sign
The willingness to answer plainly matters as much as the answers. Among the most revealing:
- Show me a process you have run that is genuinely comparable to mine.
- Show me every inspection outcome for this specific site over the last five years.
- Is my slot contractually reserved, and what happens if a larger customer wants the same window?
- Who specifically will lead the tech transfer, and what else are they running?
- What is the total cost of tech transfer, including everything you are about to tell me is out of scope?
Red flags to watch
- They cannot show you a comparable process, only a client logo.
- The inspection history is presented at corporate level, not site level.
- The slot is described as “available” rather than “reserved.”
- Your project manager carries eight other programs.
- Quality reports into operations rather than independently.
Frequently asked questions
What is the difference between a CDMO and a CMO?
A CMO, or contract manufacturing organization, provides manufacturing only. A CDMO, or contract development and manufacturing organization, also provides process development and other services, taking a product from earlier in its lifecycle through to manufacturing.
What is the most important factor when choosing a CDMO?
Technical capability for your specific modality, demonstrated by a genuinely comparable process they have run, not by a client list. Combined with a clean inspection history at the specific site, this predicts success better than price or reputation.
How long does CDMO selection take?
A properly run process takes around five months, from defining the requirement through site visits, technical and quality due diligence, and negotiating terms. Compressing it is where most mistakes are made.
Why do drugs fail in manufacturing rather than the clinic?
A significant share of Complete Response Letters cite facility, process, or validation issues rather than the drug itself. A capable molecule can still be delayed or rejected because of manufacturing problems, which is why the manufacturing partner is a critical decision.
Get the full selection playbook
We built a complete guide with the five types compared, a weighted scorecard, the five month process, all 33 questions to ask, ten red flags, and the seven contract clauses that decide what happens when something goes wrong.
